Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Maria Fleseriu, Beverly M K Biller, James W Findling, Mark E Molitch, David E Schteingart, Coleman Gross, SEISMIC Study Investigators, Timothy Lyons

Research output: Contribution to journalArticlepeer-review

273 Citations (Scopus)

Abstract

Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.
Original languageEnglish
Pages (from-to)2039-49
Number of pages11
JournalThe Journal of clinical endocrinology and metabolism
Volume97
Issue number6
DOIs
Publication statusPublished - Jun 2012

Keywords

  • Adult
  • Antihypertensive Agents
  • Blood Glucose
  • Blood Pressure
  • Body Composition
  • Body Weight
  • Cushing Syndrome
  • Diabetes Mellitus, Type 2
  • Female
  • Glucose Intolerance
  • Hormone Antagonists
  • Humans
  • Hydrocortisone
  • Hypertension
  • Male
  • Middle Aged
  • Mifepristone
  • Quality of Life
  • Quinolines
  • Receptors, Glucocorticoid
  • Urea

Fingerprint Dive into the research topics of 'Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome'. Together they form a unique fingerprint.

Cite this